|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 100 DAINGERFIELD ROAD |
Address2 | 3rd FLOOR |
| City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 27478-12
|
||||||||
|
6. House ID# 303540000
|
||||||||
| TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Karry La Violette |
Date | 7/15/2022 9:57:02 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Implementation of pharmacy provisions of Public Law 115-271;
H.R. 280, the PDMPs Help Patients Act of 2021;
H.R. 2355, the Opioid Prescription Verification Act of 2021;
H.R. 768, the Block, Report, And Suspend Suspicious Shipments Act of 2021;
Draft legislation, Ensuring Parity in E-Prescribing for Controlled Substances Across Payors;
H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Ronna |
Hauser |
|
|
|
Phillip |
Harbison |
|
|
|
Anne |
Cassity |
|
|
|
Peter |
Mihalick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 3554 / S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act;
H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act;
H.R. 2759 / S. 1362, the Pharmacy and Medically Underserved Areas Enhancement Act;
H.R. 3682, the Improving Transparency to Lower Drug Costs Act;
H.R. 2484, the Lowest Price for Patients Act;
H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act;
H.R. 19 / S. 2164, the Lower Costs, More Cures Act of 2021;
H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021;
H.R. 4121, the PRO Seniors Act;
Proposed inclusion of Medicaid managed care spread pricing prohibition to pay for H.R. 3684, the Infrastructure Investment and Jobs Act;
H.R. 5237, the Reduced Costs and Continued Cures Act of 2021
H.R. 5376, the Build Back Better Act;
H.R. 5804, the Expanding Access to Diabetes Self-Management Training Act of 2021;
H.R. 6101, the Drug Price Transparency in Medicaid Act of 2021;
Part B billing and COVID oral antivirals;
S. 3700, the Affordable Insulin Now Act;
H.R. 7213, Equitable Community Access to Pharmacist Services Act;
CY 2023 Medicare Advantage and Part D Proposed Rule (CMS-4192-P);
Draft legislation, the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office, Small Business Administration (SBA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Ronna |
Hauser |
|
|
|
Phillip |
Harbison |
|
|
|
Anne |
Cassity |
|
|
|
Peter |
Mihalick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021;
H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021;
H.R. 3656, the Vaccine Access Improvement Act of 2021;
H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021;
COVID vaccine distribution;
Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act;
H.R. 4390, the PROTECT 340B Act of 2021;
S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021;
Provider Relief Fund;
Implementation of Pubic Law 113-54, the Drug Quality and Security Act;
H.R. 6005, the Access to Birth Control Act;
H.R. 6000, Cures 2.0 Act;
H.R. 6519, Patients Right to Know Their Medication Act of 2022;
Draft legislation, Pharmacy Price Transparency Protection Act;
H.R. 7559, Prescription Information Modernization Act;
Draft legislation, To ensure that private health insurers are able to provide appropriate oversight of entities providing pharmacy benefit manager services
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), White House Office, Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Ronna |
Hauser |
|
|
|
Phillip |
Harbison |
|
|
|
Anne |
Cassity |
|
|
|
Peter |
Mihalick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
S. 617 / H.R. 1712, the Death Tax Repeal Act of 2021;
H.R. 1381 / S. 480, the Main Street Tax Certainty Act;
Draft tax provisions of FY2022 budget reconciliation legislation, including repeal of stepped up basis, S Corps/pass-throughs tax increase proposal, and 199A pass-through Deduction proposal;
Treasury Department proposal to require financial institutions reporting deposits and withdrawals of all business and personal accounts to the IRS
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of, Internal Revenue Service (IRS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phillip |
Harbison |
|
|
|
Karry |
La Violette |
|
|
|
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Peter |
Mihalick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
S. 225, the Competition and Antitrust Law Enforcement Reform Act of 2021;
S. 1388, the Prescription Pricing for the People Act of 2021;
H.R. 603 / S. 53, the Raise the Wage Act of 2021;
H.R. 7, the Paycheck Fairness Act;
Promoting Competition in the American Economy Executive Order;
UnitedHealth Group proposed merger of Change Healthcare;
Unfair Competition and Anticompetitive Contract Terms;
Occupational exposure to COVID-19 and vaccine mandates;
FTC 6(b) Study of Pharmacy Benefit Managers;
S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Federal Trade Commission (FTC), White House Office, Justice - Dept of (DOJ), Occupational Safety & Health Administration (OSHA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Karry |
La Violette |
|
|
|
Ronna |
Hauser |
|
|
|
Anne |
Cassity |
|
|
|
Phillip |
Harbison |
|
|
|
Peter |
Mihalick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
H.R. 1799, the PPP Extension Act of 2021;
H.R. 1319, the American Rescue Plan Act of 2021;
H.R. 2583, the PPP Equity Act of 2021;
Interchange Fees/Debit Routing issues;
PPP and EIDL funding
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Small Business Administration (SBA), Federal Reserve System
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phillip |
Harbison |
|
|
|
Anne |
Cassity |
|
|
|
Ronna |
Hauser |
|
|
|
Karry |
La Violette |
|
|
|
Peter |
Mihalick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |